Doubleview Capital Corp. (TSX-V: DBV) receives alleged notice of default on convertible debenture

VANCOUVER, BC—(Marketwired – August 16, 2017) – Doubleview Capital Corp. (“Doubleview”) (TSX VENTURE: DBV) announces it received a notice of an alleged event of default with respect to its convertible notes due August 1, 2018 (the “Notes”). The noteholders advise that they intend to accelerate the due date for the outstanding principal amount of the Notes and other amounts due under the Notes. Doubleview is currently reviewing the notice of default consulting its legal counsel regarding how to respond to the alleged notice of default.

About Doubleview Capital Corp.

Doubleview Capital Corp., a mineral resource exploration and development company, is based in Vancouver, British Columbia, Canada and is publicly traded on the TSX–Venture Exchange (TSX VENTURE: DBV) (OTC PINK: DBLVF) (FRANKFURT: 1D4). Doubleview identifies, acquires and finances precious and base metal exploration projects in North America, particularly in British Columbia, Canada. Doubleview increases shareholder value through acquisition and exploration of quality gold, copper and silver properties and the application of advanced state–of–the–art exploration methods. Doubleview's portfolio of strategic properties provides diversification and mitigates investment risk.

On behalf of the Board of Directors,
Farshad Shirvani, President & Chief Executive Officer

Forward–Looking Statements

Information set forth in this news release contains forward–looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Doubleview cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Doubleview's control. Such factors include, among other things: risks and uncertainties relating to Doubleview's ability to implement its exploration program on the Hat Property, limited operating history and the need to comply with environmental and governmental regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, Doubleview undertakes no obligation to publicly update or revise forward–looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cooley's Koji Fukumura Begins Term as 45th Chair of the American Bar Association Section of Litigation

NEW YORK, NY—(Marketwired – August 16, 2017) – Koji Fukumura, chair of Cooley's securities litigation practice and member of the firm's management committee, became the 45th chair of the American Bar Association Section of Litigation. The Section of Litigation is the ABA's largest section, with 50,000+ members and 40+ active committees. Fukumura was elevated from his one–year term as chair–elect to chair for the 2017–2018 bar year at the conclusion of last weekend's ABA Annual Meeting.

“Koji is a natural leader within Cooley and a dedicated and active member of the ABA,” said Michael Attanasio, chair of Cooley's global litigation department. “We are proud of his elevation and incredibly supportive of him as he carries on the section's mission of providing valuable resources for all practitioners, in particular the next generation of courtroom advocates.”

Fukumura has one of the most active securities defense practices in the US. He has 20+ years' experience in complex commercial litigation, including the defense of securities class actions, derivative suits, M&A–related class actions and government investigations. He also regularly conducts internal investigations for boards as well as their audit or special litigation committees.

“I am excited to serve our members and the profession as chair of the Section of Litigation,” said Fukumura. “I cannot recall a time in the last 50 years when it was more important to be a lawyer and protect the institutions and ideals that are fundamental to our democracy.”

The mission of the ABA Section of Litigation is to provide litigators of all practice areas the resources needed to become successful and experienced advocates. The section is dedicated to upholding the rule of law and to offering its members numerous opportunities for business networking and career advancement and a large portfolio of professional and business development products, including books, periodicals, CLEs and webinars.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high–stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Patients Are Not the #1 Target for Social Media & Other Digital Marketing Strategies, New Study Finds

RESEARCH TRIANGLE PARK, NC—(Marketwired – August 16, 2017) – A new study of pharmaceutical marketing teams found that the primary digital strategy priority is to educate and communicate with physicians, making communication with patients across digital platforms a secondary priority.

Industry data collected and analyzed by business intelligence firm, Cutting Edge Information, revealed that 80% of surveyed life science marketing teams consider healthcare physicians (HCPs) their primary target, with over 63% of surveyed teams using mobile health applications (mHealth) for physician detailing and physician education.

The study, Pharmaceutical Marketing: Reevaluate Digital Trends and Metrics for Social Media and Mobile Success, found that from the 40% of surveyed pharmaceutical marketing teams targeting patients, half (50%) of them use mobile initiatives for patient education.

“Digital marketing is a relatively new frontier for the life science industry,” said Natalie DeMasi, research team leader at Cutting Edge Information. “One of the biggest challenges in the digital marketing space is for teams to incorporate these new technologies in the restricted pharmaceutical environment.”

Data from the same study identified the second largest group (60%) targeted for digital marketing strategies as sales representatives, medical science liaisons (MSLs) and other field forces.

Cutting Edge Information's study, Pharmaceutical Marketing: Reevaluate Digital Trends and Metrics for Social Media and Mobile Success, available at https://www.cuttingedgeinfo.com/product/pharmaceutical–marketing/, explores the specific objectives, platforms and ROI metrics that life science teams employ in digital marketing. This report features analysis of exciting and potentially concerning up–and–coming trends in the digital marketing space.

This report is designed to help marketing executives:

  • Determine how to allocate your team's marketing and digital marketing budget
  • Identify key objectives and primary platforms used for social media and mHealth initiatives
  • Distinguish the most effective metrics and methods for evaluating digital marketing initiatives

For more information about pharmaceutical industry marketing, please visit https://www.cuttingedgeinfo.com/product–category/marketing/.

Image Available: http://www.marketwire.com/library/MwGo/2017/8/9/11G143964/Images/mw1bn449u8bnr11i7rnk4cjh1b4e2–4df367f1d9fba6299a983e72a0c36039.jpg
Image Available: http://www.marketwire.com/library/MwGo/2017/8/9/11G143964/Images/mw1bn448lg21lhk164l1jr24gmk22–a513ffbffadf962cbb3ee8d830d4cb07.jpg

Patients Are Not the #1 Target for Social Media & Other Digital Marketing Strategies, New Study Finds

RESEARCH TRIANGLE PARK, NC—(Marketwired – August 16, 2017) – A new study of pharmaceutical marketing teams found that the primary digital strategy priority is to educate and communicate with physicians, making communication with patients across digital platforms a secondary priority.

Industry data collected and analyzed by business intelligence firm, Cutting Edge Information, revealed that 80% of surveyed life science marketing teams consider healthcare physicians (HCPs) their primary target, with over 63% of surveyed teams using mobile health applications (mHealth) for physician detailing and physician education.

The study, Pharmaceutical Marketing: Reevaluate Digital Trends and Metrics for Social Media and Mobile Success, found that from the 40% of surveyed pharmaceutical marketing teams targeting patients, half (50%) of them use mobile initiatives for patient education.

“Digital marketing is a relatively new frontier for the life science industry,” said Natalie DeMasi, research team leader at Cutting Edge Information. “One of the biggest challenges in the digital marketing space is for teams to incorporate these new technologies in the restricted pharmaceutical environment.”

Data from the same study identified the second largest group (60%) targeted for digital marketing strategies as sales representatives, medical science liaisons (MSLs) and other field forces.

Cutting Edge Information's study, Pharmaceutical Marketing: Reevaluate Digital Trends and Metrics for Social Media and Mobile Success, available at https://www.cuttingedgeinfo.com/product/pharmaceutical–marketing/, explores the specific objectives, platforms and ROI metrics that life science teams employ in digital marketing. This report features analysis of exciting and potentially concerning up–and–coming trends in the digital marketing space.

This report is designed to help marketing executives:

  • Determine how to allocate your team's marketing and digital marketing budget
  • Identify key objectives and primary platforms used for social media and mHealth initiatives
  • Distinguish the most effective metrics and methods for evaluating digital marketing initiatives

For more information about pharmaceutical industry marketing, please visit https://www.cuttingedgeinfo.com/product–category/marketing/.

Image Available: http://www.marketwire.com/library/MwGo/2017/8/9/11G143964/Images/mw1bn449u8bnr11i7rnk4cjh1b4e2–4df367f1d9fba6299a983e72a0c36039.jpg
Image Available: http://www.marketwire.com/library/MwGo/2017/8/9/11G143964/Images/mw1bn448lg21lhk164l1jr24gmk22–a513ffbffadf962cbb3ee8d830d4cb07.jpg

UPDATE – Schuyler County Joins Growing List of New York Counties Against Opioids

WATKINS GLEN, NY—(Marketwired – August 16, 2017) – Schuyler County has become the latest New York State county to take action against the manufacturers and distributors of opioid pain killers.

The County Legislature voted Monday (August 14) to retain the firm of Napoli Shkolnik PLLC to file a lawsuit on their behalf. Schuyler County joins other New York Counties and numerous municipalities nationwide already represented by Napoli Shkolnik PLLC.

Napoli Shkolnik PLLC will work with Schuyler County Attorney Steven J. Getman, as special counsel, to bring an action against the manufacturers and distributors of prescription opiates for damages to the County arising out of the fraudulent and negligent marketing and distribution of opiates in and to the County.

“Over the past few years, despite its small population, Schuyler County has seen an uptick in opioid and heroin use and overdose,” Getman said. “To date, County officials have expended significant resources to help its residents battle opioid addiction and prevent further deaths. The lawsuit will seek to reimburse the County for its expenses related to the opioid crisis as well as provide the County with financial assistance to continue this battle.”

According to County Administrator Tim O'Hearn, the lawsuit will be filed at no risk to the County, as Napoli Shkolnik will work on contingency basis that will cover all costs associated with the lawsuit.

“By voting to go forward with litigation, the County Legislature hopes to lessen the burden to taxpayers and seeks to hold manufacturers and distributors responsible for their role in the opioid epidemic,” O'Hearn said.

“For many years the manufacturers and distributors of opioid pain medications have earned billions of dollars in profits flooding this Country with opioids,” says Napoli Shkolnik PLLC attorney Joseph L. Ciaccio. “These lawsuits seek to force those companies to help clean up the devastation caused by these pills.”

“These drug companies have poisoned our communities and polluted our children,” says Paul Napoli, of counsel for Napoli Shkolnik PLLC. Paul Napoli leads the charge with Hunter J. Shkolnik against drug companies nationwide.

“The painkiller overdose epidemic is a classic case of putting profits before people,” he said. “Many opioid manufacturers were so intent on selling as much product as possible that they either turned a blind eye towards, or intentionally buried, reports that these drugs were highly addictive and potentially deadly.”

Napoli added that “our door is open” to other New York municipalities who are also fed up with the overdose epidemic, and that Napoli Law has the firepower to go toe–to–toe with the big pharma lawyers.

Napoli has dedicated much of his career to mass tort litigation. He has fought on behalf of 9/11 injury victims at both the statehouse and the courthouse, and he and his team also took on the big energy companies which contaminated much of Long Island's drinking water supply with dangerously high levels of methyl tertiary butyl ether.